
Really provides digital diagnosis and monitoring for neurodegenerative and neuropsychiatric conditions using language and digital data. It uses machine learning and computational neuroscience to derive linguistic and behavioral biomarkers from longitudinal data. It analyzes medical, behavioral, and contextual data and targets a scalable, low-friction brain-health assessment engine. It falls under B2B SaaS for healthcare, with data sources including language and digital interactions and collaborations with researchers and drug developers. The platform aims to enable earlier detection and better trial candidate selection to improve treatment outcomes at scale.

Really provides digital diagnosis and monitoring for neurodegenerative and neuropsychiatric conditions using language and digital data. It uses machine learning and computational neuroscience to derive linguistic and behavioral biomarkers from longitudinal data. It analyzes medical, behavioral, and contextual data and targets a scalable, low-friction brain-health assessment engine. It falls under B2B SaaS for healthcare, with data sources including language and digital interactions and collaborations with researchers and drug developers. The platform aims to enable earlier detection and better trial candidate selection to improve treatment outcomes at scale.
Status: Permanently closed (listed as Closed)
Focus: Digital, non-invasive monitoring and assessment for brain health / neurodegeneration using everyday language and digital data
Technology: Machine learning + computational neuroscience to derive linguistic and behavioral digital biomarkers
Funding: Seed stage; Total funding listed as 285036 USD
Founders: Troy Kelly; Daniel Walton; Matthew Compton; Carsten Jarfelt
Detection and longitudinal monitoring of preclinical and clinical symptoms related to neurodegeneration and neuropsychiatric/neuropsychological disorders (brain health).
2016
Biotechnology
285036 USD